Press release
14.10.2019 at 16.15 local time (EEST)
The Ministry of Health of the Russian Federation's recommendation for early detection of gastrointestinal diseases is published in the Journal of Gastroenterology, Hepatology, Coloproctology. This official recommendation, published by three members of the Russian Academy of Sciences representing the Russian Gastroenterology and Oncology Organizations, describes in detail the research and treatment practices that require early detection of gastrointestinal diseases throughout the Russian Federation (1).
The recommendation of the Russian Federation contains a clear statement. Accordingly, a panel of four biomarkers (pepsinogen I, pepsinogen II, gastrin-17 and Helicobacter pylori antibody test) should be used to assess the state of gastric mucosa before undergoing gastroscopy among the low-risk patients for gastric cancer.
The GastroPanel® innovation of Biohit Oyj is the only biomarker panel of this type on the market that can reliably detect Helicobacter pylori (HP) infection and atrophic gastritis due to HP or autoimmune disease (2-11).
CEO Semi Korpela, Biohit Oyj: “The Russian Federation is one of the most important market areas of Biohit Oyj. The company already has a significant foothold in this region. The GastroPanel® test can be used to identify timely and reliably the patients suffering from upper gastrointestinal disorders who need to undergo gastroscopy. This results in significant cost savings as compared to the practice of performing gastroscopy to all patients. The simple GastroPanel® blood test is also a much more patient-friendly way to examine the status of stomach mucosa, as compared to an invasive endoscopic examination."
For more information please contact:
CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
www.biohithealthcare.com
investor.relations@biohit.fi
Biohit Oyj
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is "Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare. www.biohit.fi
References:
1. Minstery of health of Russian Federation website: https://democenter.nitrosbase.com/clinrecalg5/Files/recomend/МР108.PDF
2. www.gastropanel.com, www.biohithealthcare.com/additional-information
3. Syrjänen K, Eskelinen M, Peetsalu A, Sillakivi T, Sipponen P, Härkönen M, Paloheimo L, Mäki M, Tiusanen T, Suovaniemi O, DiMario F, Fan ZP. GastroPanel® Biomarker Panel: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. A critical review. Anticancer Res. 2019;39: 1091-1104.
4. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P. Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K and El-Omar EM: on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut 66(1): 6–30, 2017.
5. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K and Sung J: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 47(12): 136-147, 2012.
6. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis.Gut. 2015 Sep;64(9):1353-67.
7. Syrjänen K. A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36,5133-5144.
8. Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017;1-11.
9. Suovaniemi O. Hyvä Kollega. Yksityislääkäri-lehti 2006; 5:1-8 (www.biohithealthcare.com /Scientific/Literature: Search: Yksityislääkäri).
10. Suovaniemi O. State of the art GastroPanel and Acetium innovations for the unmet need. Terveyspalvelu-lehti 2011; 3-4:1-12 (https://www.biohithealthcare.com/wp-content/uploads/2019/02/state-of-the-art-gastropanel-and-acetium-innovations-suovaniemi-2011.pdf).
11. www.biohithealthcare.com / News: State of art diagnosis of Helicobacter pylori and its clinical sequels